Distribution of Acute Phase Proteins in Post-SARS CoV2 Mucormycosis Infection
Abstract
Background This study was aimed to estimate the serum levels of acute phase reactants/proteins (APR) which includes serum ferritin, C Reactive Protein, D-dimer and Procalcitonin in mucormycosis infection following SARS CoV2 infection and to determine the clinical, biochemical and histopathological findings in the same. Methods It was an observational cross-sectional study. All cases of mucormycosis following SARS CoV2 infection were reviewed. Demographic and clinical details with comorbidities and relevant laboratory investigations which included serum glucose, serum ferritin, C Reactive Protein, D-dimer, Procalcitonin were noted at the time of diagnosis of mucormycosis. Diagnosis of mucormycosis was based on frozen section examination and histopathological examination. Results Thirty-two cases of mucormycosis following SARS CoV2 infection confirmed on histopathology were studied. Majority of the cases (77%) were with comorbidity especially having diabetic mellitus type 2. C-Reactive protein, Procalcitonin and serum Ferritin were raised in almost all cases with mean of 80.92±62.5mg/l, 17.99±26.87ng/ml. and 464.9±422.03ng/ml respectively. D Dimer was raised in less than 50% cases with a mean of 828.5±245.9 ng/ml. Conclusion Acute phase proteins like C reactive Protein, Procalcitonin, Serum ferritin and D Dimer were raised in Post-SARS CoV2 infected individual who presented now with mucormycosis infection. These markers were raised markedly in critically ill patients thus indicated its pathogenetic role in severe morbidity, thus estimation of serum acute phase reactants can help in predicting the course and severity of illness.References
Dowton SB, Colten HR. Acute phase reactants in inflammation and infection. Semin Hematol 1988; 25:84–90
Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. J Pharm Bioallied Sci. 2011;3(1):118–27.
Malone L, Cm MBA, Grigorenko E, Stalons D. Id Week 2015. 2017;2(September):2633851.
Eckersall PD. Acute phase reactants. J Am Vet Med Assoc. 1991;199(6):675–6.
Symeonidis AS. The role of iron and iron chelators in zygomycosis. Clin Microbiol Infect [Internet]. 2009;15(5):26–32.
Petrikkos, George & Tsioutis, Constantinos. (2018). Recent Advances in the Pathogenesis of Mucormycoses. Clinical Therapeutics. 40. 10.1016/j.clinthera.2018.03.009.
Sugar AM. In: Mandell GL, Bennett JE, Dolin R(eds) Mandell, Douglas, and
Bennett’s principles and practice of infectious diseases (5th edn), Churchill
Livingstone, New York, USA, 2000.
Seltmann A, Troxell SA, Schad J, Fritze M, Bailey LD, Voigt CC, et al. Differences in acute phase response to bacterial, fungal and viral antigens in greater mouse-eared bats (Myotis myotis). Sci Rep [Internet]. 2022;12(1):15259
Balasopoulou A, Κokkinos P, Pagoulatos D, Plotas P, Makri OE, Georgakopoulos CD, et al. Symposium Recent advances and challenges in the management of retinoblastoma Globe ‑ saving Treatments. BMC Ophthalmol [Internet]. 2017;17(1):1.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54: S16–22.
Ibrahim AS, Voelz K. The mucormycete–host interface. CurrOpinMicrobiol. 2017; 40:40–45.
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. J Fungi (Basel). 2020 Nov 2;6(4):265.
Gokulshankar S, Bk M. Short Communication Covid-19 and Black Fungus . Asian J Med Heal Sci Vol. 2021;4(1):2–5.
Mehta, P, McAuley, DF, Brown, M, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet 2020; 395: 1033–34.
Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21(6):620–5.
Lino K, Guimarães GMC, Alves LS, Oliveira AC, Faustino R, Fernandes CS, et al. Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality. Brazilian J Infect Dis. 2021;25(2):1–6.
Revannavar SM, Supriya P, Samaga L, Vineeth K.COVID-19 triggering mucormycosis in a susceptible patient: A new phenomenon in the developing world? BMJ Case Rep. 2021;14(4). e241663.
Philipp Schuetz. The Role of Procalcitonin for Risk Assessment and Treatment of COVID-19 Patients. Health Manage. 2020;20(5):380–2.
Marwick JA, Chung KF, Adcock IM. Therapeutic Advances in Respiratory Disease as targets in respiratory disease. 2010;92:1–18.
Williams EJ et al. (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely withheld in patients admitted to hospital with SARS-CoV-2 infection. medRxiv.
Copyright (c) 2024 Deepti Dixit, Vishwanath G Shettar, Vikas Joshi, Anita P Javalgi, Vidisha S Athanikar, Kavana H
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
